Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 2, 2009, Pages 450-457

  Jacobson, Jeffrey M ^a   Kuritzkes, Daniel R ^b   Godofsky, Eliot ^c   DeJesus, Edwin ^d   Larson, Jeffrey A ^e   Weinheimer, Steven P ^f   Lewis, Stanley T ^f,g  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Bach and Godofsky   (United States)

^d IDC Research Initiative   (United States)

^e Tanox Biosystems Inc   (United States)

^f TaiMed Biologics Inc   (United States)

^g UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; ENFUVIRTIDE; IBALIZUMAB; T LYMPHOCYTE RECEPTOR; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PRIORITY JOURNAL; T CELL DEPLETION; TREATMENT RESPONSE;

ADULT; ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; AREA UNDER CURVE; CD4-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HALF-LIFE; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTES; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RNA, VIRAL; VIRUS REPLICATION; YOUNG ADULT;

EID: 59749089619     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00942-08     Document Type: Article

References (18)

1. + T-cells in chimpanzees: in vitro and in vivo characterization of MAb (IDEC-CE9.1) to human CD4. Clin.l Immunol. Immunopathol. 84:73-84.
2. Burkly, L. C., D. Olson, R. Shapiro, G. Winkler, J. J. Rosa, D. W. Thomas, C. Williams, and P. Chisholm. 1992. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody: dissecting the basis for its inhibitory effect on HIV-induced cell fusion. Immunology 149:1779-1787.
3. DeGruttola, V., L. Dix, R. D'Aquila, D. Holder, A. Phillips, M. Ait-Khaled, J. Baxter, P. Clevenbergh, S. Hammer, R. Harrigan, D. Katzenstein, R. Lanier, M. Miller, M. Para, S. Yerly, A. Zolopa, J. Murray, A. Patick, V. Miller, S. Castillo, L. Pedneault, and J. Mellors. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir. Ther. 5:41-48.
4. Delmonico, F. L., R. W. Knowles, R. B. Colvin, D. E. Cavender, T. Kawai, M. Bedle, D. Stroka, R. I. Preffer, C. Haug, and A. B. Cosimi. 1993. Immunosuppression of cynomolgus renal allograft recipients with humanized OKT4A monoclonal antibodies. Transplant. Proc. 25:784-785.
5. Fishwild, D. M., D. V. Hudson, U. Deshpande, and A. H. C. Kung. 1999. Differential effects of administration of a human anti-CD4 monoclonal antibody, HM6G, in nonhuman primates. Clin. Immunol. 92:138-152.
6. Koren, E., L. A. Zuckerman, and A. R. Mire-Sluis. 2002. Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3:349-360.
7. Kuritzkes, D. R., J. Jacobson, W. G. Powderly, E. Godofsky, E. DeJesus, F. Haas, K. A. Reimann, J. L. Larson, P. O. Yarbough, V. Curt, and W. R. Shanahan, Jr. 2004. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J. Infect. Dis. 189:286-291.
8. Lalezari, J. P., K. Henry, M. O'Hearn, J. S. Montaner, E. J. Piliero, B. Trottier, S. Walmsley, C. Cohen, D. R. Kuritzkes, J. J. Eron, Jr., J. Chung, R. DeMasi, L. Donatacci, C. Drobnes, J. Delehanty, and M. Salgo for the TORO 1 Study Group. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348:2175-2185.
9. Lazzarin, A., B. Clotet, D. Cooper, J. Reynes, K. Arasteh, M. Nelson, C. Katlama, H.-J. Stellbrink, J.-F. Delfraissy, J. Lange, L. Huson, R. DeMasi, C. Wat, J. Delehanty, C. Drobnes, and M. Salgo for the TORO 2 Study Group. 2003. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348:2186-2195.
10. LoBuglio, A. F., R. H. Wheeler, J. Trang, A. Haynes, K. Rogers, E. B. Harvey, L. Sun, J. Ghrayeb, and M. B. Khazaeli. 1989. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. USA 86:4220-4224.
11. Merkenschlager, M., D. Buck, P. C. L. Beverley, and Q. J. Sattentau. 1990. Functional epitope analysis of the human CD4 molecule. J. Immunol. 145:2839-2845.
12. M. Nelson, G. Fätkenheuer, I. Konourina, A. Lazzarin, N. Clumeck, A. Horban, M. Tawadrous, J. Sullivan, H. Mayer, and E. van der Ryst. 2007. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results. Abstr. 14th Conf. Retrovir. Opportunistic Infect., abstr. 104aLB.
13. + T-cells in chimpanzees. Clin. Immunol. 98:164-174.
14. Palella, F. J., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, S. D. Homberg, and HOPS Investigators. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
15. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2008. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, p.1-128. Department of Health and Human Services, Washington, DC.
16. Reimann, K. A., L. C. Burkly, B. Burus, B. C. D. Waite, C. I. Lord, and N. L. Letvin. 1993. In vivo administration to rhesus monkeys of a CD4-specific monoclonal antibody capable of blocking AIDS virus replication. AIDS Res. Hum. Retrovir. 9:199-207.
17. Waldman, T. A., and W. Strober. 1969. Metabolism of immunoglobulins. Prog. Allergy 13:1-110.
18. Westby, M., C. Smith-Burchnell, J. Mori, M. Lewis, M. Mosley, M. Stockdale, P. Dorr, G. Ciaramella, and M. Perros. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81:2359-2371.